Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 553

1.

The cJUN NH2-terminal kinase (JNK) signaling pathway promotes genome stability and prevents tumor initiation.

Girnius N, Edwards YJ, Garlick DS, Davis RJ.

Elife. 2018 Jun 1;7. pii: e36389. doi: 10.7554/eLife.36389.

2.

How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies.

Park JH, Ahn JH, Kim SB.

ESMO Open. 2018 May 3;3(Suppl 1):e000357. doi: 10.1136/esmoopen-2018-000357. eCollection 2018. Review.

3.

Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer.

Stover DG, Gil Del Alcazar CR, Brock J, Guo H, Overmoyer B, Balko J, Xu Q, Bardia A, Tolaney SM, Gelman R, Lloyd M, Wang Y, Xu Y, Michor F, Wang V, Winer EP, Polyak K, Lin NU.

NPJ Breast Cancer. 2018 May 4;4:10. doi: 10.1038/s41523-018-0060-z. eCollection 2018.

4.

Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation.

Vartuli RL, Zhou H, Zhang L, Powers RK, Klarquist J, Rudra P, Vincent MY, Ghosh D, Costello JC, Kedl RM, Slansky JE, Zhao R, Ford HL.

J Clin Invest. 2018 Jun 1;128(6):2535-2550. doi: 10.1172/JCI96784. Epub 2018 May 14.

5.

Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases.

De Mattos-Arruda L, Ng CKY, Piscuoglio S, Gonzalez-Cao M, Lim RS, De Filippo MR, Fusco N, Schultheis AM, Ortiz C, Viteri S, Arias A, Macedo GS, Oliveira M, Gomez P, Teixidó C, Nuciforo P, Peg V, Saura C, Ramon Y Cajal S, Casas FT, Weigelt B, Cortes J, Seoane J, Reis-Filho JS.

Oncotarget. 2018 Apr 17;9(29):20617-20630. doi: 10.18632/oncotarget.25041. eCollection 2018 Apr 17.

6.

Robust genomic copy number predictor of pan cancer metastasis.

Pearlman A, Upadhyay K, Cole K, Loke J, Sun K, Fineberg S, Freedland SJ, Shao Y, Ostrer H.

Genes Cancer. 2018 Jan;9(1-2):66-77. doi: 10.18632/genesandcancer.165.

7.

Microenvironment-Induced Non-sporadic Expression of the AXL and cKIT Receptors Are Related to Epithelial Plasticity and Drug Resistance.

Jokela TA, Engelsen AST, Rybicka A, Pelissier Vatter FA, Garbe JC, Miyano M, Tiron C, Ferariu D, Akslen LA, Stampfer MR, Lorens JB, LaBarge MA.

Front Cell Dev Biol. 2018 Apr 17;6:41. doi: 10.3389/fcell.2018.00041. eCollection 2018.

8.

Self-digitization chip for single-cell genotyping of cancer-related mutations.

Thompson AM, Smith JL, Monroe LD, Kreutz JE, Schneider T, Fujimoto BS, Chiu DT, Radich JP, Paguirigan AL.

PLoS One. 2018 May 2;13(5):e0196801. doi: 10.1371/journal.pone.0196801. eCollection 2018.

9.

Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancer.

Park IH, Kong SY, Kwon Y, Kim MK, Sim SH, Joo J, Lee KS.

J Cancer. 2018 Mar 8;9(7):1145-1151. doi: 10.7150/jca.24035. eCollection 2018.

10.

Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing.

Schuh A, Dreau H, Knight SJL, Ridout K, Mizani T, Vavoulis D, Colling R, Antoniou P, Kvikstad EM, Pentony MM, Hamblin A, Protheroe A, Parton M, Shah KA, Orosz Z, Athanasou N, Hassan B, Flanagan AM, Ahmed A, Winter S, Harris A, Tomlinson I, Popitsch N, Church D, Taylor JC.

Cold Spring Harb Mol Case Stud. 2018 Apr 2;4(2). pii: a002279. doi: 10.1101/mcs.a002279. Print 2018 Apr.

11.

Leukotriene Receptor Antagonists Inhibit Mitogenic Activity in Triple Negative Breast Cancer Cells

Suknuntha K, Yubolphan R, Krueaprasertkul K, Srihirun S, Sibmooh N, Vivithanaporn P.

Asian Pac J Cancer Prev. 2018 Mar 27;19(3):833-837.

12.

Molecular and clinical features of the TP53 signature gene expression profile in early-stage breast cancer.

Yamaguchi S, Takahashi S, Mogushi K, Izumi Y, Nozaki Y, Nomizu T, Kakugawa Y, Ishida T, Ohuchi N, Ishioka C, Kato S.

Oncotarget. 2018 Feb 8;9(18):14193-14206. doi: 10.18632/oncotarget.24447. eCollection 2018 Mar 6.

13.

c-Src inhibitor selectively inhibits triple-negative breast cancer overexpressed Vimentin in vitro and in vivo.

Lou L, Yu Z, Wang Y, Wang S, Zhao Y.

Cancer Sci. 2018 May;109(5):1648-1659. doi: 10.1111/cas.13572. Epub 2018 Apr 17.

14.

Novel putative drivers revealed by targeted exome sequencing of advanced solid tumors.

Pannuti A, Filipovic A, Hicks C, Lefkowitz E, Ptacek T, Stebbing J, Miele L.

PLoS One. 2018 Mar 23;13(3):e0194790. doi: 10.1371/journal.pone.0194790. eCollection 2018.

15.

Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer.

Patel N, Weekes D, Drosopoulos K, Gazinska P, Noel E, Rashid M, Mirza H, Quist J, Brasó-Maristany F, Mathew S, Ferro R, Pereira AM, Prince C, Noor F, Francesch-Domenech E, Marlow R, de Rinaldis E, Grigoriadis A, Linardopoulos S, Marra P, Tutt ANJ.

Nat Commun. 2018 Mar 13;9(1):1044. doi: 10.1038/s41467-018-03283-z.

16.

Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours.

Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, Zhou X, Li Y, Rusch MC, Easton J, Huether R, Gonzalez-Pena V, Wilkinson MR, Hermida LC, Davis S, Sioson E, Pounds S, Cao X, Ries RE, Wang Z, Chen X, Dong L, Diskin SJ, Smith MA, Guidry Auvil JM, Meltzer PS, Lau CC, Perlman EJ, Maris JM, Meshinchi S, Hunger SP, Gerhard DS, Zhang J.

Nature. 2018 Mar 15;555(7696):371-376. doi: 10.1038/nature25795. Epub 2018 Feb 28.

PMID:
29489755
17.

Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer.

Siegel MB, He X, Hoadley KA, Hoyle A, Pearce JB, Garrett AL, Kumar S, Moylan VJ, Brady CM, Van Swearingen AE, Marron D, Gupta GP, Thorne LB, Kieran N, Livasy C, Mardis ER, Parker JS, Chen M, Anders CK, Carey LA, Perou CM.

J Clin Invest. 2018 Apr 2;128(4):1371-1383. doi: 10.1172/JCI96153. Epub 2018 Feb 26.

18.

Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers.

Mundt F, Rajput S, Li S, Ruggles KV, Mooradian AD, Mertins P, Gillette MA, Krug K, Guo Z, Hoog J, Erdmann-Gilmore P, Primeau T, Huang S, Edwards DP, Wang X, Wang X, Kawaler E, Mani DR, Clauser KR, Gao F, Luo J, Davies SR, Johnson GL, Huang KL, Yoon CJ, Ding L, Fenyö D, Ellis MJ, Townsend RR, Held JM, Carr SA, Ma CX.

Cancer Res. 2018 May 15;78(10):2732-2746. doi: 10.1158/0008-5472.CAN-17-1990. Epub 2018 Feb 22.

PMID:
29472518
19.

New therapeutic strategies to treat human cancers expressing mutant p53 proteins.

Blandino G, Di Agostino S.

J Exp Clin Cancer Res. 2018 Feb 15;37(1):30. doi: 10.1186/s13046-018-0705-7. Review.

20.

Predictors of breast cancer cell types and their prognostic power in breast cancer patients.

Wang F, Dohogne Z, Yang J, Liu Y, Soibam B.

BMC Genomics. 2018 Feb 13;19(1):137. doi: 10.1186/s12864-018-4527-y.

Supplemental Content

Support Center